ArticleEpidemiology and health2016
Visceral leishmaniasis treatment outcome and its determinants in northwest Ethiopia.
Article in Epidemiology and health, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Prevalence estimates of human immunodeficiency virus (HIV) infection among visceral leishmaniasis infected people in Northwest Ethiopia: a systematic review and meta-analysis.BMC infectious diseases · 2020Pooled it
- Treatment outcomes of visceral leishmaniasis in Ethiopia from 2001 to 2017: a systematic review and meta-analysis.Infectious diseases of poverty · 2018Pooled it
- Prevalence, antimicrobial resistance, and public health risk assessment of zoonotic bacterial pathogens in raw cattle meat from three zonal cities in Tigray, Ethiopia.BMC microbiology · 2025Article
- Clinical Profiles and Outcomes of rK39-Confirmed Paediatric Visceral Leishmaniasis at a General Hospital in Massawa, Eritrea: A Retrospective Study.International journal of general medicine · 2025Article
- Time to recovery from visceral leishmaniasis and its predictors of mature visceral leishmaniasis patients admitted at Metema Hospital, Metema, Ethiopia.Scientific reports · 2024Article
- Treatment Outcomes of Single-Dose Liposomal Amphotericin B-Treated Visceral Leishmaniasis Patients and Factors Affecting Outcome in Bihar, India.The American journal of tropical medicine and hygiene · 2024Article
- Barriers and facilitators of visceral leishmaniasis case management in the Amhara Region, Northwest Ethiopia: an exploratory qualitative study.BMC public health · 2024Article
- Hematological and Clinical Features Associated with Initial Poor Treatment Outcomes in Visceral Leishmaniasis Patients with and without HIV Coinfection in Gondar, Northwest Ethiopia.Tropical medicine and infectious disease · 2023Article
- Bioprospecting marine actinomycetes for antileishmanial drugs: current perspectives and future prospects.Heliyon · 2021Review
- Efficacy and safety of a combined treatment of sodium stibogluconate at 20mg/kg/day with upper maximum daily dose limit of 850mg and Paromomycin 15mg/kg/day in HIV negative visceral leishmaniasis patients. A retrospective study, northwest Ethiopia.PLoS neglected tropical diseases · 2021Article
- Inequalities of visceral leishmaniasis case-fatality in Brazil: A multilevel modeling considering space, time, individual and contextual factors.PLoS neglected tropical diseases · 2021Article
- Infectivity and Drug Susceptibility Profiling of DifferentPathogens (Basel, Switzerland) · 2020Article
- Incidence of Mortality and Its Predictors Among Adult Visceral Leishmaniasis Patients at the University of Gondar Hospital: A Retrospective Cohort Study.Infection and drug resistance · 2020Article
- Cutaneous leishmaniasis a neglected tropical disease: community knowledge, attitude and practices in an endemic area, Northwest Ethiopia.BMC infectious diseases · 2019Article
- Discovery of novel hit compounds with broad activity against visceral and cutaneous Leishmania species by comparative phenotypic screening.Scientific reports · 2019Article
- Relationship of Serum Antileishmanial Antibody With Development of Visceral Leishmaniasis, Post-kala-azar Dermal Leishmaniasis and Visceral Leishmaniasis Relapse.Frontiers in microbiology · 2019Article
- Visceral Leishmaniasis Treatment Outcome and Associated Factors in Northern Ethiopia.BioMed research international · 2019Article
- A preliminary survey of major diseases of ruminants and management practices in Western Tigray province, northern Ethiopia.BMC veterinary research · 2018Article
- Leishmaniasis in Ethiopia: A systematic review and meta-analysis of prevalence in animals and humans.Heliyon · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesPoor treatment outcomes of visceral leishmaniasis (VL) are responsible for the high mortality rate of this condition in resource-limited settings such as Ethiopia. This study aimed to identify the proportion of poor VL treatment outcomes in northwest Ethiopia and to evaluate the determinants associated with poor outcomes.
methodsA hospital-based retrospective study was conducted among 595 VL patients who were admitted to Kahsay Abera Hospital in northwest Ethiopia from October 2010 to April 2013. Data were entered into Epi Info version 7.0 and exported to SPSS version 20 for analysis. Bivariate and multivariate logistic regression models were fitted to identify the determinants of VL treatment outcomes. Adjusted odds ratio (aORs) with 95% confidence intervals (CIs) were used, and
resultsThe proportion of poor treatment outcomes was 23.7%. Late diagnosis (≥29 days) (aOR, 4.34; 95% CI, 2.22 to 8.46), severe illness at admission (inability to walk) (aOR, 1.63; 95% CI, 1.06 to 2.40) and coinfection with VL and human immunodeficiency virus (HIV) (aOR, 2.72; 95% CI, 1.40 to 5.20) were found to be determinants of poor VL treatment outcomes.
conclusionsPoor treatment outcomes, such as death, treatment failure, and non-adherence, were found to be common. Special attention must be paid to severely ill and VL/HIV-coinfected patients. To improve VL treatment outcomes, the early diagnosis and treatment of VL patients is recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.